Clinical Trial

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Name: Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL — clinical trial record (NCT05147467)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL.

Protocol Amendment History 7 amendments

This ClinicalTrials.gov record has been amended 7 times since 2021-11-24; most recent amendment 2026-03-24.

Status change: Not Yet Recruiting → Recruiting 2022-03-16

Trial Details

NCT Number	NCT05147467
Lead Sponsor	Ascentage Pharma Group Inc.
Conditions	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment	75 participants
Start Date	2021-12-28
Primary Completion	2026-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-27